AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

10.420

-0.470-4.32%

Volume:109.46K

Turnover:1.15M

Market Cap:523.09M

PE:16.19

High:10.990

Open:10.700

Low:10.300

Close:10.890

52wk High:13.933

52wk Low:8.350

Shares:50.20M

Float Shares:41.32M

Volume Ratio:0.71

T/O Rate:0.26%

Dividend:0.05

Dividend Rate:0.48%

EPS(TTM):0.644

EPS(LYR):0.718

ROE:13.96%

ROA:10.62%

PB:2.10

PE(LYR):14.51

Loading ...

Overview Company News Filings

Clinuvel highlights CUV105 vitiligo study case reports showing repigmentation with afamelanotide plus NB-UVB

ASX Growth Stocks With High Insider Ownership In April 2026

Simply Wall St.

ASX Growth Stocks With Strong Insider Ownership

Simply Wall St.

ASX Growth Stocks With High Insider Ownership And 102% Earnings Surge

Simply Wall St.

Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

Exploring Appen And 2 Promising Tech Stocks With High Growth Potential

Simply Wall St.

Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders

THOMSON REUTERS

Clinuvel Pharmaceuticals - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO

THOMSON REUTERS

Morgans says these small-cap ASX shares could rise 30% to 80%

A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results

Simply Wall St.

Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings

Simply Wall St.

BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales

Clinuvel H1 net profit after tax AUD 10.4 million -26%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CUV.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":10.42,"timestamp":1787292720000,"preClose":10.89,"halted":0,"volume":109462,"delay":0,"changeRate":-0.04315886134067958,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"Not Yet Opened","change":-0.47,"latestTime":"08-21 16:12:00 AEST","open":10.7,"high":10.99,"low":10.3,"amount":1153118,"amplitude":0.063361,"askPrice":10.97,"askSize":500,"bidPrice":10.3,"bidSize":325,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.89,"dividendRate":0.004798,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.709792966784423,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":10.89,"auctionPrice":10.42,"auctionVolume":9329,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":0.709792966784423,"shares":50200740,"dividePrice":0.05,"high":10.99,"amplitude":0.063361,"preClose":10.89,"low":10.3,"week52Low":8.35,"pbRate":"2.10","psRate":"5.43","week52High":13.933,"institutionHeld":0,"latestPrice":10.42,"committee":-0.212121,"eps":0.643659,"divideRate":0.004798,"volume":109462,"delay":0,"ttmEps":0.643659,"open":10.7,"prevYearClose":12.46,"prevWeekClose":9.55,"prevMonthClose":9.06,"prevQuarterClose":10.28,"fiveDayClose":9.55,"twentyDayClose":10.06,"sixtyDayClose":8.96,"earningDate":1787760000000,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624652656","title":"Clinuvel highlights CUV105 vitiligo study case reports showing repigmentation with afamelanotide plus NB-UVB","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652656?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:37","pubTimestamp":1775093850,"startTime":"0","endTime":"0","summary":"Clinuvel highlighted clinical updates from AAD 2026, where afamelanotide data were already presented across its vitiligo program and its marketed EPP franchise.CUV105 vitiligo case studies presented at meeting showed repigmentation with treatment, with pigment maintenance in darker skin types for up to six months following therapy withdrawal.Long-term EPP analyses presented at AAD supported a consistent safety profile for SCENESSE, with no signal of drug-related malignancies reported across more than 21,000 doses.Management positioned relapse risk on withdrawal of JAK inhibitor therapies as a competitive consideration, citing need for sustained dosing to maintain vitiligo response.Clinuvel introduced an AI-driven Vitiligo Visual Algorithm at conference, with refinement planned to support future study execution including planned CUV107.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9w25YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624549425","title":"ASX Growth Stocks With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624549425","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624549425?lang=en_us&edition=fundamental","pubTime":"2026-04-02 03:08","pubTimestamp":1775070503,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of recovery with a significant 101-point advance, optimism is building around the potential resolution of Middle East tensions and its positive impact on global indices. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, aligning well with investor interests during times of economic uncertainty.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-ownership-in-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-ownership-in-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7129","CYC.AU","BK7005","BK7007","FEX.AU","DVP.AU","BK7110","BK7104","EIQ.AU","BK7126","BK7508","BK7067","XAO.AU","BK7062","PNV.AU","BK7095","TOR.AU","XKO.AU","IMA.AU","FRS.AU","XJO.AU","AR1.AU","CUV.AU","AV1.AU","BK7162","BK7016","MAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624320635","title":"ASX Growth Stocks With Strong Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624320635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624320635?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:08","pubTimestamp":1774984084,"startTime":"0","endTime":"0","summary":"As the Australian market faces a cautious start, with investors closely monitoring decisions from the Reserve Bank and Fair Work Commission, the performance of growth stocks remains a focal point for many. In such uncertain economic conditions, companies with strong insider ownership can be particularly appealing as they often indicate confidence in the firm's future prospects.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-stocks-with-strong-insider-ownership-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-stocks-with-strong-insider-ownership-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IPX.AU","BK7503","BK7067","BK7126","EIQ.AU","BK7095","AYA.AU","FRS.AU","BK7007","AV1.AU","NAN.AU","BK7016","FEX.AU","MAU.AU","BK7110","BK7094","BK7104","BK7017","BK7129","BK7116","CUV.AU","TOR.AU","BK7508","AEM.AU","CYC.AU","AR1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623350905","title":"ASX Growth Stocks With High Insider Ownership And 102% Earnings Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2623350905","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623350905?lang=en_us&edition=fundamental","pubTime":"2026-03-30 03:08","pubTimestamp":1774811308,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a turbulent phase, with shares poised for a decline amid geopolitical tensions and natural disruptions affecting key sectors. In such uncertain times, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, potentially offering resilience and long-term potential amidst market volatility.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/1032000-choice2-main-header/1585186674409","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/1032000-choice2-main-header/1585186674409"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-tbn/tamboran-resources-shares/news/asx-growth-stocks-with-high-insider-ownership-and-102-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-tbn/tamboran-resources-shares/news/asx-growth-stocks-with-high-insider-ownership-and-102-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7036","BK7007","BK7067","BK7104","BK7142","AR1.AU","TBN.AU","BK7095","XJO.AU","BK4213","BK7508","XAO.AU","BK7110","AEM.AU","TPW.AU","TBN","BK7017","AV1.AU","FEX.AU","FRS.AU","BK7107","BK7016","TOR.AU","CUV.AU","XKO.AU","BK7049","CYC.AU","MAU.AU","TTT.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622894932","title":"Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals","url":"https://stock-news.laohu8.com/highlight/detail?id=2622894932","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622894932?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:54","pubTimestamp":1774562051,"startTime":"0","endTime":"0","summary":"Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals. Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6GH32Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REG.AU","AR1.AU","BK7007","FRS.AU","BK7017","BK7129","TLX","AV1.AU","BK7104","BK7095","BK7067","TLX.AU","AEM.AU","BK7016","BK7110","BK4526","BK7113","BK4139","CYC.AU","BK4531","BK4108","EIQ.AU","MAU.AU","TOR.AU","BK4552","CUV.AU","IQ","FEX.AU","BK7508","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895958","title":"Exploring Appen And 2 Promising Tech Stocks With High Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895958?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:05","pubTimestamp":1774551958,"startTime":"0","endTime":"0","summary":"Amidst a cautiously optimistic Australian market, with the ASX 200 showing modest gains due to ongoing geopolitical uncertainties, investors are keeping a close eye on sectors poised for growth despite the broader sentiment. In this environment, high-growth tech stocks like Appen and others can be particularly appealing as they offer potential for significant returns by leveraging innovative solutions and adapting swiftly to changing market dynamics.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7503","AI","BK4551","BK4585","FCL.AU","CHAT","BK7016","BK4587","BK7508","BK4528","BK7061","BK4023","AIPO","BK4588","AIYY","BK4543","APX.AU","CUV.AU","BK7067","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852860","title":"Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852860?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:46","pubTimestamp":1774525563,"startTime":"0","endTime":"0","summary":"Parmantier & Cie. initiated an update on Clinuvel with a Buy recommendation and a 12-month target price of AUD 24.Analysts Thomas Schiessle and Daniel Grojohann cited revenue growth of 4% and an OPEX increase of 22%.EPS was reported down 26% alongside higher development-related spending.NEURACTHEL Instant  was described as a planned second revenue source with potential of USD 150 million.Philippe Wolgen was expected to continue as CEO, and a Nasdaq Level II ADR uplisting was described as in progress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on March 26, 2026, and is solely responsible for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9k833R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277043","title":"ASX 300 healthcare stock outperforming today on 'strategic' leadership news","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277043","media":"MotleyFool","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277043?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:00","pubTimestamp":1773964847,"startTime":"0","endTime":"0","summary":"Over the past 12 months, shares in the ASX 300 healthcare stock have slumped 20% Addressing that decline, Rosenfeld said, \"Market data tell a clear story: pre-revenue biotechs often outperform as perception and hope dominates investment decisions, while profitable companies executing quietly can be undervalued.\" He added: The board, market analysts, and sophisticated institutions recognise that our share price does not reflect the company's performance. It reflects a perceived ceiling on further growth. Our job, and Philippe's, is to break through that ceiling.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","CUV.AU","BK7067","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277689","title":"Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277689","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277689?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:29","pubTimestamp":1773962952,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  confirmed that Philippe Wolgen will remain chief executive, citing his scientific expertise, regulatory experience, and steady leadership as vital for guiding the company through its key growth phase, according to a Friday Australian bourse filing.The company's shares were up 1% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620927483","title":"Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927483?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620274866","title":"Clinuvel Pharmaceuticals  - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274866?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027485","title":"Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027485?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027294","title":"Morgans says these small-cap ASX shares could rise 30% to 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027294?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:57","pubTimestamp":1773795437,"startTime":"0","endTime":"0","summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CUV.AU","RDY.AU","BK7067","BK7508","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647249","title":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647249?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:20","pubTimestamp":1773015634,"startTime":"0","endTime":"0","summary":"Why Clinuvel’s latest half year result has caught investor attention\nClinuvel Pharmaceuticals (ASX:CUV) has drawn fresh interest after reporting half year earnings to 31 December 2025, with revenue of A$40.56 million and net income of A$10.44 million, both below the prior period.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nAt a share price of A$10.16, Clinuvel’s recent half year result lands against a backdrop of weaker momentum, with a 30 day share price return of 8.14% and a 90...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617599594","title":"Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617599594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617599594?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:48","pubTimestamp":1772678913,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals Limited announced the availability of an investor and analyst webinar  discussing its financial results for the six months ended 31 December 2025, hosted at 18:00 AEDT on 26 February 2026, posted at CLINUVEL news website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL7ks45p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHL.AU","BK7089","IMM.AU","FPH.AU","XAO.AU","BK7103","IDX.AU","XBI","XKO.AU","HLS.AU","COH.AU","CSL.AU","BK7126","ANN.AU","MVF.AU","BK4585","LABU","BK4588","BK7007","BK7501","BK7067","CU6.AU","NHF.AU","XLV","BK7511","BK7096","BK7508","BK7124","BK7509","BK4581","TLX.AU","BK7113","MSB.AU","CUV.AU","RHC.AU","HCAR","NEU.AU","XJO.AU","REG.AU","MPL.AU","SIG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616447918","title":"Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2616447918","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616447918?lang=en_us&edition=fundamental","pubTime":"2026-03-01 04:29","pubTimestamp":1772310599,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) is in focus after a key European Medicines Agency approval for year round SCENESSE use in erythropoietic protoporphyria, alongside fresh half year earnings that show revenue of A$40.56 million and net income of A$10.44 million.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nEven with the EMA approval and fresh half year numbers, sentiment around Clinuvel looks cautious. A 1 day share price return of 9.33% decline and a year to date share price return...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614288815","title":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2614288815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614288815?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:54","pubTimestamp":1772168074,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales** Shares of drug maker Clinuvel Pharmaceuticals CUV.AX slip as much as 8.24% to A$10.130, lowest since July 8, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL6N3ZN0AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614205062","title":"Clinuvel H1 net profit after tax AUD 10.4 million -26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614205062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614205062?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:04","pubTimestamp":1772075090,"startTime":"0","endTime":"0","summary":"Clinuvel reported record December-half sales revenues of AUD 36.9 million in the six months to 31 December 2025 (+4%), with total revenue of AUD 40.6 million. Expenses rose to AUD 26.0 million , and net profit after tax fell to AUD 10.4 million , with basic earnings per share of AUD 0.21 . Cash and term deposits increased to AUD 233.0 million (+4%), and the balance sheet remained free of external borrowings. The company said higher spending reflected expansion plans and increased R&D activity, with personnel costs up 16% and clinical and non-clinical development costs up 19%. Commercial distribution expenses rose 42%, and finance and legal expenses increased 47%, primarily linked to an application to the U.S. SEC to upgrade its Level I ADRs to Level II for a NASDAQ listing. Management also highlighted preparation for larger markets in vitiligo and first entry to market for NEURACTHEL, an ACTH analogue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL1H6Ww2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":82,"code":"91000000","status":"200"}]}}